Shares of Siemens (SIEGY) dropped over 14% in 2015, but a recent Street-beating earnings report has given the German turbine-maker’s stock a jolt. Kevin Kelly, managing partner at Recon Capital, said the positive energy driving the stock will continue. 'What Siemens demonstrated is that they are doing well in this current market environment both on the top and bottom lines,' said Kelly. 'And they are providing tremendous value, especially when you compare it to GE (GE).' Siemens profit soared to 1.56 billion euros ($1.71 billion) in the company's fiscal first quarter, from 1.10 billion euros in 2014. The profit figure beat the Wall Street consensus estimate of 1.05 billion euros. Kelly is also bullish on German drug-maker Bayer AG (BAYRY), which has seen its shares fall over 24% in the last 12 months. Bayer has spent a great deal on cancer drug research and Kelly expects that R&D to begin paying off in 2016. 'They have great generics – think of aspirin – but they also have tremendous drugs that are helping people fight diseases,' said Kelly. TheStreet's Gregg Greenberg has details from Wall Street.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.